Interim Analysis (IA) of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients (Pts) with High-Risk Large B Cell Lymphoma (LBCL)
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Sattva S. Neelapu, Michael Dickinson, Matthew L. Ulrickson, Olalekan O. Oluwole, Alex F. Herrera, Catherine Thieblemont, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Yin Yang, Francesca Milletti, Lovely Goyal, Jun Kawashima, Jul Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research